Navigation Links
National Library of Medicine Awards Phase I SBIR Grant to Collaborative Drug Discovery, Inc. to Develop Computational Tools for Biocomputation across Distributed Private Datasets to Enhance Drug Discovery
Date:9/13/2011

BURLINGAME, Calif., Sept. 13, 2011 /PRNewswire/ -- Collaborative Drug Discovery (CDD), a provider of a web-based drug discovery software platform, announced they have been awarded a grant for a software development project focused on ADME/Tox and tuberculosis drug discovery data sharing.

The Phase I Small Business Innovation Research (SBIR) grant from the National Library of Medicine, part of the National Institutes of Health, is part of a program to enable sharing of biological data.

"Following our valuable collaboration with Pfizer, which resulted in the paper "Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties" (1) and several publications on tuberculosis computational models (2-6), we realized there was an opportunity to use CDD to host and selectively share computational models" said Sean Ekins, Ph.D., D.Sc., Collaborations Director, CDD. "Our collaborators at Pfizer have demonstrated that computational models generated for very large datasets with open cheminformatics tools were equivalent to those generated with commercial tools and thus provides a way to potentially share models in a platform agnostic manner".

"The grant will fund proof of concept work using Open source cheminformatics tools in collaboration with pharmaceutical and not for profit groups and will build on our pioneering work of secure selective sharing of data on the cloud," said Barry Bunin, president & CEO of CDD. "This project extends our work on TB and is complementary with our goal bringing groups together to collaborate and share their data when desirable.  The technology will extend the existing innovations selectively sharing data, to selectively sharing models, even without sharing or even uploading sensitive data." "It has the potential to remove barriers between precompetitive and competitive markets and this grant will enable us to further enhance how the cloud is used and develop a new product in the future".

The project described was supported by Award Number 1R43LM011152-01 from the National Library of Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Library of Medicine or the National Institutes of Health.

About Collaborative Drug Discovery, Inc.CDD (www.collaborativedrug.com) provides the most widely used web-based drug discovery software platform on the market. "CDD Vault™" is the secure, private industrial-strength database combining traditional drug discovery informatics (registration and SAR) with social networking capabilities. "CDD Collaborate™" enables real-time collaboration by securely exchanging selected confidential data with external researchers. "CDD Public™" enables researchers to mine a unique aggregation of information from a variety of scientific data providers.References(1)

Rishi R. Gupta, Gifford, EM, Liston T, Waller CL, Hohman M, Bunin BA and Ekins S, Using open source computational tools for predicting human metabolic stability and additional ADME/Tox properties, Drug Metab Dispos, 38: 2083-2090, 2010.(2)

Ekins S and Freundlich JS, Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets, Pharm Res, 28, 1859-1869, 2011.(3)

Lamichhane G, Freundlich JS, Ekins S , Wickramaratne N, Nolan, S and Bishai WR, Essential Metabolites of M. tuberculosis and their small molecule mimics, Mbio, 2: e00301-10, 2011.(4)

Ekins S, Freundlich JS, Choi I, Sarker M and Talcott C, Computational Databases, Pathway and Cheminformatics Tools for Tuberculosis Drug Discovery, Trends In Microbiology, 19: 65-74, 2011.(5)

Ekins S, Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol Biosyst, 6: 2316-2324, 2010.(6)

Ekins S, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Hohman M  and Bunin BA, A Collaborative Database and Computational Models for Tuberculosis Drug Discovery, Mol BioSyst, 6: 840-851, 2010.
'/>"/>

SOURCE Collaborative Drug Discovery, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
8. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
9. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
10. September is National Pain Awareness Month
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):